[New Drug] A new option for the treatment of heart failure—vericiguat

Heart failure is a severe clinical syndrome associated with high mortality and readmission rates. Although traditional drug interventions have delayed the progression of heart failure and improved clinical symptoms, some patients still have poor quality of life and poor prognosis. Novel oral soluble guanylate cyclase stimulator, primarily used to treat patients with chronic heart failure and reduced ejection fraction. This drug is the first soluble guanylate cyclase (sGC) agonist to treat patients with worsening chronic heart failure. It is well tolerated by patients and has good safety profile, and is worthy of clinical application and promotion.

In a clinical trial, all patients were randomly assigned to the vericiguat 2.5 mg/d group or the placebo group in a 1:1 ratio after a 0-30 day screening period. Based on the patient's blood pressure and clinical symptoms, the dose of vericiguat was gradually increased to the target dose of 10 mg/d. Median follow-up was 10.8 months.

The trial results showed that the incidence of the primary endpoint (the composite endpoint of death from cardiovascular causes or first hospitalization for heart failure) was 35.5% in the vericiguat group and 38.5% in the placebo group. Vericiguat reduced the risk of the primary endpoint event by 10%, with a hazard ratio HR (95% confidence interval CI) of 0.90. Combining the above tests, it can be seen that vericiguat can reduce the risk of death, improve the patient's quality of life and disease progression, have a positive effect on the patient's condition, and has a significant therapeutic effect.

The above is an introduction to vericiguat. If patients want to know more about vericiguat drug information (such as purchase channels, drug prices, precautions, etc.), they can consult the medical companion travel service at any time.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: